Search

Your search keyword '"McLaurin, Brent"' showing total 185 results

Search Constraints

Start Over You searched for: Author "McLaurin, Brent" Remove constraint Author: "McLaurin, Brent"
185 results on '"McLaurin, Brent"'

Search Results

1. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications

2. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

4. Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III

5. Patients With Diabetes at High Bleeding Risk With 1-Month Dual Antiplatelet Therapy: Onyx ONE Clear Results

6. Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus

7. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

8. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

9. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

10. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications

12. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients

14. Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry (Clinical Research in Cardiology, (2022), 111, 5, (560-573), 10.1007/s00392-022-01996-2)

16. Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy

17. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

18. Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy)

19. TCT-316 Impact of Geographic Variation on the Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent: Results From the PIONEER III Clinical Trial in North America, Europe, and Japan

20. TCT-290 Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus: Results From the PIONEER III Clinical Trial

21. Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions: 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)

23. Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes

24. Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial

25. Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial

27. SIMILAR OUTCOMES WITH THE SUPREME™BIODEGRADABLE DRUG COATED CORONARY STENT SYSTEM IN ACUTE CORONARY SYNDROME AND CHRONIC CORONARY SYNDROMES: RESULTS OF THE PROSPECTIVE MULTICENTER RANDOMIZED CONTROLLED PIONEER III TRIAL

28. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial

29. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial

30. Bivalirudin for patients with acute coronary syndromes

32. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events

33. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial

35. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

36. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

37. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

38. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

39. Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial

40. Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial.

41. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

42. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

43. The Changing Landscape for Stroke Prevention in AF Findings From the GLORIA-AF Registry Phase 2

45. Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: Insights from the ACUITY trial

46. Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes

47. Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial

48. IMPACT OF PRIOR CHRONIC ANTIPLATELET THERAPY ON SHORT- AND LONG-TERM ADVERSE EVENTS IN PATIENTS PRESENTING WITH AN ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ACUITY TRIAL

49. DRUG-ELUTING VERSUS BARE-METAL STENTS IN TREATMENT OF DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROMES: ANALYSIS FROM THE RANDOMIZED ACUITY TRIAL

Catalog

Books, media, physical & digital resources